Investment Note: Gene editing in focus
Why I like BEAM, CRSP and NTLA
The Next Medical Revolution — and an Alternative to an Uncertain AI Trade
November 16, 2026 | Investment horizon: 2027–2028
A potentially historic turning point in medicine
Over the past several years, much of the investment world's attention and capital has been concentrated on artificial intelligence, semiconductors, data centres and the enormous infrastructure required to support them.
While AI will undoubtedly remain an important technological revolution, I believe another transformation is unfolding that may ultimately prove just as significant to humanity: the ability to treat, correct and potentially cure serious diseases by editing human genes.
This is no longer simply theoretical science.
Three publicly traded biotechnology companies—Beam Therapeutics (NASDAQ: BEAM), CRISPR Therapeutics (NASDAQ: CRSP) and Intellia Therapeutics (NASDAQ: NTLA)—are approaching important milestones that could help move genetic medicine from specialized experimental treatments toward broader commercial adoption.
Two years ago I took positions in all three, with BEAM as my principal investment, CRSP as the more commercially established complement and NTLA as the higher-risk, potentially higher-reward opportunity. I exited those positions in favor of the Ai buildout trade. I am now considering entering positions again.
1. Beam Therapeutics (BEAM): My first choice
Beam is developing base editing, a technology designed to make precise changes to individual DNA letters without requiring the conventional double-strand DNA cuts associated with earlier CRISPR approaches.
This potentially provides a more precise way of addressing the genetic causes of disease.
On November 10, 2026, Beam announced positive pivotal results for risto-cel, its investigational sickle-cell treatment. The trial met its primary efficacy and safety endpoints, and the company expects to submit its FDA application as early as year-end 2026.
Equally important is BEAM-302, which aims to correct the underlying genetic defect responsible for alpha-1 antitrypsin deficiency, a serious inherited condition affecting the lungs and liver. Early clinical evidence suggests the treatment is producing the intended biological effects.
Beam reported approximately US$1 billion in cash and marketable securities at September 30, 2026. Its projected funding runway extends into mid-2029, including a conditional financing draw.
Why I am interested: Beam combines a potentially revolutionary technology platform with increasingly convincing clinical evidence, several development programs and sufficient financial resources to pursue major milestones.
I also believe its proprietary technology could make it an attractive strategic acquisition candidate for a larger pharmaceutical company seeking to expand into genetic medicine.
2. CRISPR Therapeutics (CRSP): The commercial validation
CRISPR Therapeutics has already achieved something that many biotechnology companies spend decades pursuing: bringing a gene-editing medicine to market.
Its CASGEVY treatment, developed with Vertex Pharmaceuticals, is approved for eligible patients with sickle cell disease and transfusion-dependent beta thalassemia.
CASGEVY generated approximately US$99 million in product revenue during the third quarter of 2026, representing 30% sequential growth. More than 750 patients worldwide had initiated treatment.
CRSP is also developing CTX310, an investigational in-body gene-editing treatment targeting serious lipid disorders. If successful, its applications could extend beyond rare genetic diseases into much larger cardiovascular markets.
The company reported approximately US$2.28 billion in cash and marketable securities, although part of that balance reflects convertible-debt financing.
Why I am interested: CRSP provides tangible evidence that gene-editing medicine can become a commercial business. Its substantial financial resources, expanding pipeline and relationship with Vertex strengthen the long-term investment case.
A potential acquisition by Vertex or another pharmaceutical company is conceivable, although existing partnerships may reduce the need for a full takeover.
3. Intellia Therapeutics (NTLA): The potentially historic catalyst
Intellia may be approaching one of the most consequential regulatory milestones in genetic medicine.
Its investigational lonvo-z treatment is designed to provide a one-time therapy for hereditary angioedema, a serious disorder that causes recurrent swelling attacks.
In Phase 3 testing, the treatment reduced attacks by approximately 87% compared with placebo over six months.
The FDA has accepted Intellia's application, with a target decision date of March 10, 2027.
If approved, lonvo-z could become the world's first commercially approved treatment that uses CRISPR to edit genes directly inside the human body.
That distinction is enormously important. Rather than removing cells, modifying them in a laboratory and returning them to the patient, in-body gene editing offers the prospect of simpler treatment delivery for certain diseases.
Intellia also has a strategic relationship with Regeneron Pharmaceuticals.
Why I am interested: NTLA offers the possibility of a major regulatory and commercial breakthrough within months. Its comparatively smaller market capitalization could make successful commercialization particularly meaningful to shareholders.
However, the company has experienced safety concerns in a separate gene-editing program, and FDA approval is not assured. I would therefore treat NTLA as the smallest and most speculative of the three investments.
4. Why Big Pharma could become interested
Large pharmaceutical companies face a continuing challenge: important medicines eventually lose patent protection, exposing billions of dollars in annual revenue to generic and biosimilar competition.
Acquiring innovative biotechnology companies is one way to replenish their development pipelines and obtain technologies that could underpin future generations of treatments.
Gene editing is especially attractive because it offers the possibility of treating diseases at their genetic source rather than managing symptoms indefinitely.
I see three potential reasons for acquisition interest:
Proprietary technology: A successful gene-editing platform could generate numerous future medicines, making the technology itself strategically valuable.
Clinical and regulatory validation: As treatments demonstrate efficacy and obtain approvals, some of the uncertainty facing potential acquirers diminishes.
Access to new markets: Successful gene-editing therapies for cardiovascular, metabolic and other widespread diseases could create much larger commercial opportunities than today's initial rare-disease applications.
Beam's base-editing platform, CRSP's approved treatment and Intellia's in-body editing capabilities each represent different strategic opportunities.
Existing relationships involving Pfizer, Eli Lilly, Vertex and Regeneron illustrate the pharmaceutical industry's interest in these technologies.
I consider Beam the most interesting potential acquisition candidate, followed by Intellia and CRISPR Therapeutics. This is a judgment about strategic attractiveness, not evidence of current acquisition discussions.
Importantly, my investment thesis does not depend on a takeover. These businesses must ultimately create value through successful medicines, commercialization and sustainable economics.
5. Why consider these investments now, amid the Nvidia controversy?
The timing of this opportunity is particularly interesting.
Nvidia's co-founder Jensen Huang resigned in November following reports concerning his personal conduct and allegations involving a suspected foreign-intelligence connection.
The controversy has raised questions about corporate governance, leadership succession and Nvidia's future strategic direction. The intelligence-related allegations remain unproven, and Nvidia has stated that it has no reason to believe company secrets were compromised.
More broadly, investors are increasingly questioning the financial structure supporting the AI infrastructure boom.
Enormous capital commitments, complex financing arrangements, circular investment relationships and uncertainty about future returns on AI spending have created concern about whether the market has become excessively dependent on a relatively small number of technology companies.
I do not believe this necessarily means the AI revolution is ending.
However, a temporary correction in AI-related equities could encourage investors to reconsider where the next major technological and commercial opportunities will emerge.
Genetic medicine offers a compelling alternative.
Unlike an AI infrastructure investment, whose immediate financial prospects may depend on continued data-centre construction and semiconductor spending, biotechnology companies can experience substantial valuation changes following successful clinical trials, FDA approvals and commercial adoption.
Their catalysts are different.
This does not make biotechnology immune to market corrections. Smaller biotechnology stocks are often highly sensitive to interest rates, liquidity and investor risk appetite. A broad technology selloff could initially drag biotechnology shares lower as well.
Nevertheless, over a two-year horizon, I believe successful genetic-medicine companies could develop investment momentum based on their own medical and commercial achievements, rather than the trajectory of AI infrastructure spending.
6. My proposed investment approach
I favour taking positions gradually rather than attempting to predict the precise bottom in any of these stocks.
Within a dedicated speculative genetic-medicine allocation, my preferred weighting would be:
| Company | Allocation | Investment role |
|---|---|---|
| BEAM | 45% | Primary technology and growth position |
| CRSP | 40% | Commercial validation and broader pipeline |
| NTLA | 15% | Higher-risk regulatory and takeover optionality |
I would initially establish partial positions and retain capital to take advantage of market weakness or additional clinical evidence.
There are meaningful risks: disappointing trial results, regulatory setbacks, unexpected safety problems, expensive commercialization, dilution and prolonged operating losses. The three companies also share substantial exposure to the same emerging field, making this a concentrated investment rather than a diversified healthcare portfolio.
7. My investment conclusion
I believe we may be approaching an important inflection point in genetic medicine.
For decades, many inherited diseases could be managed but not fundamentally corrected. Today, companies such as Beam, CRISPR Therapeutics and Intellia are demonstrating that this limitation may increasingly be overcome.
The medical implications are extraordinary, and the commercial implications could be substantial.
At the same time, uncertainty surrounding Nvidia, the financing of the AI infrastructure boom and the concentration of market capital in a handful of technology companies makes it sensible to investigate other sources of long-term growth.
My interest in BEAM, CRSP and NTLA is therefore based on three converging opportunities:
The transition of gene editing from experimental science toward commercial medicine.
The possibility that major pharmaceutical companies will increasingly seek to acquire or partner with developers of proprietary genetic technologies.
The opportunity to diversify growth capital into a potentially transformative industry whose fundamental catalysts differ from those driving the AI infrastructure trade.
I regard BEAM as my first choice, CRSP as my second and NTLA as a smaller, higher-risk third position.
The next 24 months could prove particularly important as regulatory decisions, clinical results and commercialization provide clearer evidence of which companies will become leaders in genetic medicine.
The opportunity is substantial, but success is not assured. I would pursue these investments with a multi-year horizon, disciplined position sizing and a willingness to reassess the thesis as clinical and financial evidence develops.
The central investment proposition is simple: while markets debate the next phase of artificial intelligence, a revolution in the treatment of human disease may already be entering its commercial era.
Investment research note — November 16, 2026. This reflects a speculative investment thesis, not guaranteed returns or confirmed takeover interest.
Research supporting the note
The principal clinical and financial information comes from the companies' November 2026 disclosures: Beam's pivotal clinical results, CRISPR Therapeutics' Q3 results and Intellia's Q3 results.
For the Nvidia discussion, Reuters reports Huang's resignation and the related governance concerns, while distinguishing allegations from established wrongdoing. Reuters also identifies investor scrutiny of AI financing arrangements and Nvidia's leadership transition
Ed Note:
I would not disregard the possible takeover value of these three as their cutting edge technology develops and commercializes. Big Pharma is always on the lookout for such tasty morsels!
